Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab biosimilar evaluated by network meta-analysis.

Literature DB >> 28935845

Rituximab biosimilar evaluated by network meta-analysis.

Marco Chiumente¹, Daniele Mengato², Andrea Messori³.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2017 PMID： 28935845 PMCID： PMC5709121 DOI： 10.3324/haematol.2017.175042

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

Keyword Cloud
References

× No keyword cloud information.

11 in total

1. Delivering affordable cancer care in high-income countries.

Authors: Richard Sullivan; Jeffrey Peppercorn; Karol Sikora; John Zalcberg; Neal J Meropol; Eitan Amir; David Khayat; Peter Boyle; Philippe Autier; Ian F Tannock; Tito Fojo; Jim Siderov; Steve Williamson; Silvia Camporesi; J Gordon McVie; Arnie D Purushotham; Peter Naredi; Alexander Eggermont; Murray F Brennan; Michael L Steinberg; Mark De Ridder; Susan A McCloskey; Dirk Verellen; Terence Roberts; Guy Storme; Rodney J Hicks; Peter J Ell; Bradford R Hirsch; David P Carbone; Kevin A Schulman; Paul Catchpole; David Taylor; Jan Geissler; Nancy G Brinker; David Meltzer; David Kerr; Matti Aapro
Journal: Lancet Oncol Date: 2011-09 Impact factor: 41.316

2. Biosimilars: A consideration of the regulations in the United States and European union.

Authors: Justin Daller
Journal: Regul Toxicol Pharmacol Date: 2015-12-28 Impact factor: 3.271

Review 3. Biosimilar: what it is not.

Authors: Fernando de Mora
Journal: Br J Clin Pharmacol Date: 2015-06-04 Impact factor: 4.335

4. "Total evidence" network meta-analysis as a tool for improving the assessment of biosimilars: application to etanercept in rheumatoid arthritis .

Authors: Andrea Messori; Sabrina Trippoli; Claudio Marinai
Journal: Int J Clin Pharmacol Ther Date: 2017-06 Impact factor: 1.366

Review 5. Safety and efficacy of biosimilars in oncology.

Authors: Huub Schellekens; Josef S Smolen; Mario Dicato; Robert M Rifkin
Journal: Lancet Oncol Date: 2016-11 Impact factor: 41.316

6. Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.

Authors: Morgane Beck; Bruno Michel; Marie-Christine Rybarczyk-Vigouret; Dominique Levêque; Christelle Sordet; Jean Sibilia; Michel Velten
Journal: BioDrugs Date: 2016-12 Impact factor: 5.807

Review 7. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.

Authors: Rena M Conti; William V Padula; Richard A Larson
Journal: Ann Hematol Date: 2015-03-27 Impact factor: 3.673

Rituximab biosimilar evaluated by network meta-analysis.

1. Delivering affordable cancer care in high-income countries.

2. Biosimilars: A consideration of the regulations in the United States and European union.

Review 3. Biosimilar: what it is not.

4. "Total evidence" network meta-analysis as a tool for improving the assessment of biosimilars: application to etanercept in rheumatoid arthritis .

Review 5. Safety and efficacy of biosimilars in oncology.

6. Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.

Review 7. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.

Review 8. The high price of anticancer drugs: origins, implications, barriers, solutions.

9. Network meta-analysis: a norm for comparative effectiveness?

Review 10. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.

Rituximab biosimilar evaluated by network meta-analysis.

1. Delivering affordable cancer care in high-income countries.

2. Biosimilars: A consideration of the regulations in the United States and European union.

Review 3. Biosimilar: what it is not.

4. "Total evidence" network meta-analysis as a tool for improving the assessment of biosimilars: application to etanercept in rheumatoid arthritis .

Review 5. Safety and efficacy of biosimilars in oncology.

6. Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.

Review 7. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.

Review 8. The high price of anticancer drugs: origins, implications, barriers, solutions.

9. Network meta-analysis: a norm for comparative effectiveness?

Review 10. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.

4. "Total evidence" network meta-analysis as a tool for improving the assessment of biosimilars: application to etanercept in rheumatoid arthritis .